We are a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Our proprietary Tailored Covalency® platform enables us to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities that we believe will rival those of injectable biologics, yet maintain the convenience of a pill. Our strategy is to advance the development of our proprietary drug candidates, and for certain programs, use collaborations and partnerships as strategic tools to maximize the value of those assets.
Company Details
- Employees
- 18
- Founded
- -
- Address
- 220 E Grand Ave, South San Francisco,california 94080,united States
- Industry
- Biotechnology
- Website
- http://www.principiabio.com
- HQ
- South San Francisco, California
Principia Biopharma Questions
Principia Biopharma's website is http://www.principiabio.com
Principia Biopharma's LinkedIn profile is https://www.linkedin.com/company/principia-biopharma
Principia Biopharma has
18 employees.
View email and phone details for 18
employees at Principia Biopharma.
Principia Biopharma's industry is
Biotechnology
Principia Biopharma's top competitors are
Hi-Bio: A Biogen Company,
Amgen,
Pharmacyclics, An Abbvie Company,
Exelixis,
Nurix Therapeutics,
Genentech,
Principia,
Kura Oncology, Inc.,
Alumis,
Cymabay Therapeutics.
Principia Biopharma's categories are Biotechnology
Principia Biopharma's founding year is 2008
